Gravar-mail: GENETICALLY-ENGINEERED PIGS AS SOURCES FOR CLINICAL RED BLOOD CELL TRANSFUSION: WHAT PATHOBIOLOGICAL BARRIERS NEED TO BE OVERCOME?